



Human Immunodeficiency Virus Type 1 (HIV-1) GenoSure Archive

LABORATORIES

Patient: [REDACTED]
DOB: [REDACTED] Age: 64 Gender: M
Patient Identifiers: [REDACTED]
[REDACTED]
Visit Number (FIN): [REDACTED]

Client: [REDACTED]
Physician: [REDACTED]

ARUP Test Code: 3002503
Collection Date: 06/16/2021
Received in lab: 06/24/2021
Completion Date: 07/07/2021

TEST INFORMATION

Test performed at Labcorp Monogram Biosciences, 345 Oyster Point Blvd., South San Francisco, CA 94080

PATIENT REPORT

Patient's results continue on following page(s).



Patient: [REDACTED]
ARUP Accession: 21-173-403447

Weidong Huang, MD, Medical Director
 345 Oyster Point Blvd
 South San Francisco, CA 94080 - Tel: (800) 777-0177

Client: [REDACTED]
 Phone: (800) 242-2787

Project: [REDACTED]
 Fax: (801) 584-5132

Patient Name	DOB	Patient ID/Medical Record #	Gender	Monoqram Accession #
[REDACTED]	[REDACTED]	[REDACTED]	M	[REDACTED]
Date Collected	Date Received	Date Reported	Mode	Report Status
16-JUN-2021 12:39	25-JUN-2021 10:19 PT	07-JUL-2021 09:21 PT	F,L,W	FINAL
Referring Physician	Reference Lab ID/Order #			
[REDACTED]	21-173-403447			
Comments	HIV-1 Subtype: B			

	Generic Name	Brand Name	Assessment	Drug Resistance Associated Mutations Detected	Comments
NRTI	Abacavir	Ziagen	Sensitive	M184M/V	
	Didanosine	Videx	Resistance Possible	M184M/V	
	Emtricitabine	Emtriva	Resistant	M184M/V	
	Lamivudine	Epivir	Resistant	M184M/V	
	Stavudine	Zerit	Sensitive	None	1
	Tenofovir	Viread	Sensitive	None	1
	Zidovudine	Retrovir	Sensitive	None	1
NNRTI	Doravirine	Pifeltro	Sensitive	I135T	
	Efavirenz	Sustiva	Sensitive	None	
	Etravirine	Intelence	Sensitive	None	
	Nevirapine	Viramune	Sensitive	None	
	Rilpivirine	Eduvant	Sensitive	None	
INI	Bictegravir	Bictegravir	Sensitive	None	
	Dolutegravir	Tivicay	Sensitive	None	
	Elvitegravir	Vitekta	Sensitive	None	
	Raltegravir	Isentress	Sensitive	None	
PI	Atazanavir	Reyataz / r*	Sensitive	None	
	Darunavir	Prezista / r*	Sensitive	None	
	Fosamprenavir	Lexiva / r*	Sensitive	None	
	Indinavir	Crixivan / r*	Sensitive	None	
	Lopinavir	Kaletra*	Sensitive	None	
	Nelfinavir	Viracept	Sensitive	None	
	Ritonavir	Norvir	Sensitive	None	
	Saquinavir	Invirase / r*	Sensitive	None	
	Tipranavir	Aptivus / r*	Sensitive	None	



Weidong Huang, MD, Medical Director
 345 Oyster Point Blvd
 South San Francisco, CA 94080 - Tel: (800) 777-0177

Client: [REDACTED] Project: [REDACTED]
 Phone: (800) 242-2787 Fax: (801) 584-5132

Patient Name	DOB	Patient ID/Medical Record #	Gender	Monoqram Accession #
[REDACTED]	[REDACTED]	[REDACTED]	M	[REDACTED]
Date Collected	Date Received	Date Reported	Mode	Report Status
16-JUN-2021 12:39	25-JUN-2021 10:19 PT	07-JUL-2021 09:21 PT	F,L,W	FINAL

* Assessment of drug susceptibility is based upon detected mutations and interpreted using an advanced proprietary algorithm (version 18).
 † Interpretation algorithms for ritonavir-boosted protease inhibitors appropriate for the following dosages: AMP/r 600mg/100mg BID; ATV/r 300mg/100mg QD; IDV/r 800mg/200mg BID; LPV/r 400mg/100mg BID; SQV/r 1000mg/100mg BID; TPV/r 500mg/200mg BID; and DRV/r 600mg/100mg BID.
 * **Mixtures** are indicated by amino acids separated by a slash. Deletions in the amino acid sequence are indicated by a ^ symbol.

NRTI			M 184 M V
NNRTI	I 135 T		

Summary of Mutations Observed

RT V35I/T, Q102K, I135T, C162S, E169E/G, M184M/V, F214L, R277K, T286A, V293I, M357T, K358R, A376T, V381V/I, K390R, A400T
IN D6E, E11D, S17N, V113I, S119P/T, T124N, V234L, D253E, D256E
PR T12P, L19T, M36M/T, N37N/S, P39P/S, L63P, I93L

Genotype Comments (clinical significance may vary)

1 Assessment for this drug was derived considering the sensitizing effect of mutation M184V.

For more information on interpreting this report, please visit www.MonogramBio.com or call Customer Service at 800-777-0177 between the hours of 6:30am to 5:00pm PT Monday through Friday.

GenoSure Archive is a DNA sequencing assay that uses next-generation sequencing to analyze the protease (amino acids 1-99), reverse transcriptase (amino acids 1-400) and integrase (amino acids 1-288) coding regions derived from HIV-1 cell associated DNA. Subtype is determined using the protease and reverse transcriptase sequence information. This assay meets the standards for performance characteristics and all other quality control and assurance requirements established by CLIA. The results should not be used as the sole criteria for patient management. This test was developed and its performance characteristics determined by Monogram Biosciences. It has not been cleared or approved by the FDA. This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 800-777-0177.

